EC17 for Intraoperative Imaging for Parathyroidectomy
Primary Purpose
Primary Hyperparathyroidism
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
EC17
Sponsored by
About this trial
This is an interventional diagnostic trial for Primary Hyperparathyroidism focused on measuring Primary hyperparathyroidism, Parathyroid
Eligibility Criteria
Inclusion Criteria:
- Adult patients over 18 years of age
- Patients presenting with primary hyperparathyroidism presumed to be resectable on pre-operative assessment
- Good operative candidate
- Subject capable of giving informed consent and participating in the process of consent.
Exclusion Criteria:
- Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery
- Patients with a history of anaphylactic reactions to Folate-FITC or insects
Vulnerable patient populations
- Homeless patients
- Patients with drug or alcohol dependence
- Children and neonates
- Patients unable to participate in the consent process
Sites / Locations
- Hospital of the University of Pennsylvania
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
EC17 Injection Group
Arm Description
The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
Outcomes
Primary Outcome Measures
The ability of EC17 and the imaging system to detect FRA positive tumors during surgery conducted 2-4 hours post EC-17 administration.
Secondary Outcome Measures
The number of participants that will have an adverse reaction to EC17
Full Information
NCT ID
NCT01996072
First Posted
November 21, 2013
Last Updated
June 29, 2018
Sponsor
University of Pennsylvania
1. Study Identification
Unique Protocol Identification Number
NCT01996072
Brief Title
EC17 for Intraoperative Imaging for Parathyroidectomy
Official Title
A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pennsylvania
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can be difficult due to the variant location of the parathyroid glands. Up to 5% of patients leave the operating room without surgical cure.
Primary hyperparathyroidism is an ideal disease to investigate intraoperative fluorescent imaging. This would allow surgeons to identify the parathyroid glands and resect the suspicious parathyroid glands. Folate receptor (FR) has been found to be over-expressed in parathyroid tissue and not thyroid issues. An ideal surgical treatment would combine FR-specific fluorescent tracers with intraoperative imaging. It is important to note that FR is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. Thus, the false positive detection rate is expected to be extremely low.
A group well known to us in the Netherlands has completed a pilot study utilizing a folate-FITC conjugate in 12 patients with ovarian cancer. Another group of investigators in Mayo have subsequently performed this study on 20 more patients without any serious adverse events (personal communication). They report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). All side effects reversed when the injection was halted. Patients with a history of allergic reactions to insect bites should not participate (fluorescein is derived from the firefly insect, folate is an essential vitamin).
A fluorescent contrast agent (folate-FITC or EC17) will be used to determine if it will localize to the primary tumor nodule(s) or mass(es) of patients undergoing parathyroid surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Hyperparathyroidism
Keywords
Primary hyperparathyroidism, Parathyroid
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
EC17 Injection Group
Arm Type
Experimental
Arm Description
The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
Intervention Type
Drug
Intervention Name(s)
EC17
Other Intervention Name(s)
Folate- FITC
Primary Outcome Measure Information:
Title
The ability of EC17 and the imaging system to detect FRA positive tumors during surgery conducted 2-4 hours post EC-17 administration.
Time Frame
Within two to four hours of injection of EC17
Secondary Outcome Measure Information:
Title
The number of participants that will have an adverse reaction to EC17
Time Frame
Day 1-Day 30
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients over 18 years of age
Patients presenting with primary hyperparathyroidism presumed to be resectable on pre-operative assessment
Good operative candidate
Subject capable of giving informed consent and participating in the process of consent.
Exclusion Criteria:
Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery
Patients with a history of anaphylactic reactions to Folate-FITC or insects
Vulnerable patient populations
Homeless patients
Patients with drug or alcohol dependence
Children and neonates
Patients unable to participate in the consent process
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sunil Singhal, M.D.
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Learn more about this trial
EC17 for Intraoperative Imaging for Parathyroidectomy
We'll reach out to this number within 24 hrs